Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical pipeline is focused on restoring or improving the cell's ability to produce energy in cardiometabolic disorders where energetic impairment is a fundamental contributor to disease pathogenesis, symptoms and functional deficits. The lead product candidate, ninerafaxstat, has completed multiple Phase 2 clinical trials in three indications: non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and heart failure with preserved ejection fraction (HFpEF). In Phase 1 and 2 clinical trials, ninerafaxstat was shown to be well tolerated.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/10/25	$57,500,000	Series B	AN Ventures Catalio Capital Cytokinetics Deep Track Capital RA Capital Management SV Health Investors	undisclosed